Drug Monitoring Program
AUGUST UPDATE: Maryland’s PDMP will be fully operational in autumn, 2013. Pharmacies and healthcare practitioners that dispense controlled substances may now register to create an online account to report prescription information to the PDMP. For more information, please see the RxSentry Dispenser’s Implementation Guide on our new PDMP website.
The website also contains the PDMP’s implementation timeline and will soon be updated with information on how physicians, nurse practitioners, pharmacists and other users will get access to prescription information.
On May 10, 2011, Governor Martin O’Malley signed into law Senate Bill 883, legislation to create a Prescription Drug Monitoring Program (PDMP) in Maryland. The goal of the PDMP is to reduce the non-medical use, abuse and diversion of prescription drugs while preserving the professional practice of healthcare providers and legitimate patient access to optimal pharmaceutical-assisted care. The PDMP will monitor the prescribing and dispensing of controlled dangerous substances (drugs with abuse potential), including opioid pain relievers like oxycodone (OxyContin, Percocet, Percodan, Roxicet), hydrocodone (Vicodin, Lortab) and methadone prescribed for pain, psychotherapeutics like alprazolam (Xanax) and diazepam (Valium), and stimulants like Adderall and Ritalin.
The program will make prescription information available only to a limited group of individuals and agencies responsible for ensuring the health and welfare of patients and the lawful use of controlled substances. For the first time, comprehensive information on controlled substances prescribed and dispensed will be available to doctors, pharmacists and other healthcare providers. The PDMP will provide a powerful clinical tool for the prevention, early identification and treatment of prescription drug abuse and addiction. The program will also assist investigations by law enforcement, licensing and regulatory agencies into illegal drug diversion, healthcare fraud, illegitimate professional practice and other issues that affect public health and safety.
In partnership with government agencies, universities, non-profits, professional societies and other stakeholders, the PDMP will develop and make available training and educational resources on the appropriate clinical use of controlled substances and prescription drug-related substance use disorders to healthcare practitioners, policymakers, researchers and the general public.